Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6880479 | 0.83 | KMT2A (0.52) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL3627806 | 0.82 | DCK (0.43) | RAB9ATSHRL3MBTL1KMT2ANPC1 | |
| SCHEMBL10348673 | 0.81 | MAPK14 (0.44) | RAB9ATSHRL3MBTL1KMT2ANPC1 | |
| SCHEMBL8303938 | 0.78 | ABCB1 (0.40) | RAB9ATSHRL3MBTL1KMT2ANPC1 | |
| SCHEMBL27622346 | 0.77 | RAB9A (0.37) | RAB9ATSHRL3MBTL1KMT2ANPC1 | |
| SCHEMBL27603628 | 0.76 | PTGS2 (0.36) | RAB9ATSHRL3MBTL1KMT2ANPC1 | |
| SCHEMBL12882196 | 0.74 | KMT2A (0.48) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL210468 | 0.73 | RAB9A (0.51) | RAB9ATSHRL3MBTL1KMT2ANPC1 | |
| SCHEMBL5694141 | 0.72 | DYRK1A (0.47) | RAB9ATSHRL3MBTL1KMT2ANPC1 | |
| SCHEMBL7264255 | 0.71 | RAB9A (0.41) | RAB9ATSHRL3MBTL1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104736551-B | The method for preparing oligomeric compounds using improved end-blocking scheme | IONIS制药公司 | 2017-07-28 | — | — | CN | claimed |
| EP-2885312-A1 | METHOD OF PREPARING OLIGOMERIC COMPOUNDS USING MODIFIED CAPPING PROTOCOLS | Isis Pharmaceuticals, Inc. (US) | 2015-06-24 | — | — | EP | claimed |
| WO-2014028739-A1 | METHOD OF PREPARING OLIGOMERIC COMPOUNDS USING MODIFIED CAPPING PROTOCOLS | ISIS PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | WO | claimed |
| US-6809195-B1 | COMPRISES A MODIFIED PHOSPHORAMIDITE PROTOCOL IN WHICH OXIDATION AND CAPPING STEPS ARE COMBINED INTO A SINGLE STEP; INCREASED EFFICIENCY; SOLID PHASE SYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2004-10-26 | — | — | US | claimed |
| US-20030229220-A1 | Oligomer phosphoramidite compositions and processes for synthesizing the same | RAVIKUMAR VASULINGA T (US) | 2003-12-11 | — | — | US | claimed |
| US-6610842-B1 | Removing hydroxyl protecting group from compound of given formula and treating with another compound; wide range of diagnostic and therapeutic uses | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | claimed |
| EP-1311526-A1 | PROCESSES FOR THE PREPARATION OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2003-05-21 | — | — | EP | claimed |
| EP-1244682-A4 | PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2003-02-05 | — | — | EP | claimed |
| EP-1244682-A1 | PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-02 | — | — | EP | claimed |
| EP-1175432-A4 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHOSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS INC (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2002014340-A1 | PROCESSES FOR THE PREPARATION OF OLIGONUCLEOTIDES_______________ | ISIS PHARMACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | claimed |
| EP-1175432-A1 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHUSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2002-01-30 | — | — | EP | claimed |
| WO-2001049701-A1 | PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| WO-2000068241-A1 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHUSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-16 | — | — | WO | claimed |
| WO-1995029930-A2 | IMPROVED METHOD FOR OLIGONUCLEOTIDE ANALOG SYNTHESIS | GILEAD SCIENCES, INC. (US) | 1995-11-09 | — | — | WO | claimed |
| EP-4349846-A1 | CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024064858-A2 | COMPOUNDS AND METHODS FOR REDUCING MECP2 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2001002415-A1 | C3'-METHYLENE HYDROGEN PHOSPHONATE MONOMERS AND RELATED COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000068241-A1 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHUSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000004034-A2 | OLIGONUCLEOTIDES HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229220-A1 | Oligomer phosphoramidite compositions and processes for synthesizing the same | PHOSPHO1, OSGEP, DTYMK | RAB9A 4222/4885TSHR 3963/4885L3MBTL1 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.